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Abstract Cryptococcosis remains a significant cause of mor-
bidity and mortality among HIV-infected patients, especially in
sub-Saharan Africa where it causes up to 20% of AIDS-related
deaths in HIV programs. A new, highly sensitive, and afford-
able point of care diagnostic test for cryptococcal infection, the
lateral flow assay, can detect early sub-clinical cryptococcosis
especially in areas with limited laboratory infrastructure.With a
prevalence of detectable sub-clinical cryptococcal infection av-
eraging 7.2 % (95 % CI 6.8–7.6 %) among 36 cohorts with
CD4 <100 cells/μL in Africa, together with data showing that
preemptive fluconazole prevents overt cryptococcal disease in
this population, implementing a screen and treat strategy as part
of HIV care practice among patients with CD4 <100 cells/μL
could prevent the incidence of often fatal cryptococcal menin-
gitis in the setting of the HIV pandemic.
Keywords HIV . Cryptococcosis . Cryptococcal antigen .
Fluconazole . CD4 . CRAG screening . Preemptive therapy
Introduction
One of the most significant contributors to the increased bur-
den of cryptococcosis worldwide is indisputably HIV infec-
tion. With 35.3 million individuals living with HIV and an
estimated peak of 2.3 million HIV-associated deaths in 2012
[1], the rise in the incidence of opportunistic infections has
been remarkable, resulting in tremendous strain on healthcare
resources and lost lives and income especially in low- and
middle-income countries (LMICs).
Prior to the global HIV epidemic, cryptococcosis was a
disease primarily of individuals with low immunity, particu-
larly after long-term use of immunosuppressive drugs and
solid-organ transplantation, with other non-HIV risk factors
including hematopoietic or other malignancies, innate im-
mune defects, advanced liver or renal disease, sarcoidosis,
rheumatologic disease, and diabetes mellitus [2–9]. One of
the initial indicators of the HIV epidemic was the increase in
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cases of cryptococcal meningitis (CM) [10–12]. Although the
incidence of CM has decreased in high-income countries with
the advent of antiretroviral therapy (ART), sub-Saharan Africa
continues to grapple with a high prevalence of HIV and op-
portunistic infections, with cryptococcal meningitis as the
leading cause of meningitis among HIV-infected adults [3,
13, 14]. Over the last 3 decades of the HIV epidemic, efforts
have been invested in improving cryptococcal care with revi-
sion of national guidelines focusing on diagnosis and manage-
ment of cryptococcal meningitis but less so on prevention.
Fluconazole prophylaxis given to HIV-infected patients
with CD4 <200 cells/μL before or during ART has been
shown to reduce the risk of developing cryptococcal menin-
gitis, including using thrice-weekly fluconazole dosing [15•,
16]. However, this strategy is not as cost-effective as targeted
cryptococcal antigen (CRAG) screening followed by preemp-
tive therapy using fluconazole in the setting of cryptococcal
antigenemia [17•, 18•]. Although currently only recommend-
ed in HIV-infected persons, it is also possible that CRAG
screening and preemptive fluconazole therapy would be ben-
eficial in solid-organ transplantation patients.
Preventing new HIV infections, early HIV diagnosis,
implementing early linkage to care, ensuring timely initiation
of ARTwith strict adherence, and adequate patient follow-up
along the continuum of HIV care would ideally prevent inci-
dent cryptococcosis and other opportunistic infections. In this
review, we outline the strategies for preventing cryptococcosis
in the context of HIV infection and discuss the impact of new
cryptococcal diagnostics on these strategies.
Burden of Cryptococcal Disease
Cryptococcus is an encapsulated yeast acquired by inhalation
that can disseminate to cause a severe meningoencephalitis
primarily in people with defective cell-mediated immunity.
Cryptococcus neoformans is responsible for most human
disease and has a worldwide distribution with an ecological
niche in decaying organic matter and soil containing bird
excrement [19].
In high-income country (HIC) settings, including the USA,
Western Europe, and Australia, cryptococcosis emerged dur-
ing the HIVepidemic in the 1980s as a cause of meningitis in
5–10 % of HIV-infected individuals [20, 21]. Rollout of ART
starting in 1997 led to a dramatic decline in cases, illustrated
by a greater than 90 % decreased incidence in a large UK
cohort in 2006–2007 compared to 1996–1997 [14]. A review
of over 200million US hospital admissions from 1997 to 2009
similarly found a 5.8 % annual decline of HIV-associated CM
and proportional rise in non-HIV CM over this period from 16
to 29 % of all cases (major risk factors including solid-organ
transplant and long-term use of corticosteroids or other immu-
nosuppressant drugs) [3]. Early case-fatality rate of CM in
HICs with access to amphotericin-based induction therapy
(±flucytosine) is as low as 10 % in clinical trials, when ex-
cluding lost to follow-up [22, 23•]. This decline is yet to be
demonstrated in LMICs.
The vast majority of cryptococcal meningitis cases and
deaths occur in LMICs with high HIV prevalence coupled
with common delays in HIV diagnosis and ART initiation.
Recent data suggests that well over 90 % of cryptococcal
meningitis cases in LMICs are in people infected with HIV
[13, 24–26]. In 2006, of an estimated 957,900 HIV-associated
CM cases and 624,725 deaths worldwide, more than 90 % of
cases and 95% of deaths occurred in sub-Saharan Africa (720,
000 cases, 504,000 deaths), South and Southeast Asia (120,
000 cases, 66,000 deaths), and Latin America (54,400 cases,
29,900 deaths) [23•]; however, these estimates are currently
under revision. Cryptococcus is the leading cause of meningi-
tis in much of Southern and Eastern Africa and causes up to
20 % of deaths in HIV-infected cohorts from sub-Saharan
Africa [13, 27–29]. Health facilities in LMICs often lack
amphotericin-based induction therapy (instead using high-
dose fluconazole) and are under-resourced for performing se-
rial lumbar punctures and monitoring common side effects of
antifungal treatment, all of which contribute to poor treatment
outcomes. Park et al. previously estimated a 3-month case-
fatality rate in LMICs at 55 and 70 % in sub-Saharan Africa
[23•]. More recent reports suggest continued poor treatment
outcomes, with in-hospitalmortality of 27.9% in a study from
Burkina Faso, 52.0 % in Cameroon, 48.1 % in Ethiopia,
50.0 % in India, 35.8 % in Kenya, 62.2 % in Senegal, and
40.5 % in South Africa [24, 26, 30–34].
Asymptomatic Cryptococcosis
Cryptococcosis is one of the few infectious diseases in which
the presence of disseminated infection can be demonstrated
even while patients remain asymptomatic. Asymptomatic
cryptococcosis (positive serum CRAGwith absent or minimal
symptoms) is a sub-clinical infectious state known to precede
clinically apparent disease by weeks to months and is strongly
associated with risk of incident meningitis and all-cause mor-
tality [35, 36•, 37]. Cryptococcal antigenemia is common in
persons with AIDS and is inversely related to CD4 count
(Table 1) [41, 43, 44, 49, 54]. In sub-Saharan Africa, patients
with CD4 ≤100 cells/μL have a CRAG prevalence reported
between 2.2 and 21.0 % or up to 11.5 % in studies including
only asymptomatic, ART-naïve patients [35, 36•, 38, 39•,
40–47, 55].
In Southeast Asia, CRAG prevalence in patients with
CD4 ≤100 cells/μL is reported between 4.0 and 20.6 % or up
to 12.9 % in studies including only asymptomatic, ART-naïve
patients [48–52]. In untreated asymptomatic antigenemic pa-
tients starting ART, over 25 % go on to develop incident
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cryptococcal meningitis within 12 months versus as few as
0 % of CRAG-negative patients [36•]. Baseline cryptococcal
antigenemia is also a strong independent predictor of mortality
in the first year of ART after adjusting for baseline clinical
(e.g., CD4 count) and demographic factors, with a study from
Indonesia, including only patients without initial symptoms of
meningitis, showing an adjusted hazard ratio for death of 2.6
(95 % CI 1.4–4.6) and a study from South Africa showing an
adjusted hazard ratio of 3.2 (95 % CI 1.5–6.6) [36•, 51]. A
Ugandan study of ART-naïve, TB/HIV co-infected patients
followed for 2 years found an adjusted hazard ratio for death
of 4.27 (95 % CI 1.5–12.1) in those who were CRAG positive
at baseline [56]. For pre-ART asymptomatic CRAG-positive
patients, another Ugandan study found a relative risk of death
(within 12 weeks after ART initiation) of 6.6 (95 % CI 1.9–
23.6) compared to pre-ART CRAG-negative patients [35].
Robust evidence is lacking to guide the optimal manage-
ment of patients found to have asymptomatic cryptococcal
antigenemia, but expert guidelines suggest using 800 mg of
fluconazole for 2 weeks followed by 400 mg for 8 weeks [57].
These guidelines have been adopted with some variation by
several countries (Table 2).
The Changing Landscape of Cryptococcal
Diagnostics
Historically, cryptococcal infection has been diagnosed by
India ink microscopy, latex agglutination for cryptococcal an-
tigen, or culture. Culture is ultimately considered to be the
gold standard; however, delays in obtaining a result make
culture clinically unhelpful for initial management decisions.
CRAG assays include enzyme immunoassay (EIA), latex ag-
glutination (LA), or a recently developed point-of-care lateral
flow assay (LFA) (IMMY, Inc., Norman, Oklahoma), which
was approved by the US Food and Drug Administration for
use with CSF or serum in July 2011. The test utilizes an
immunochromatographic test strip containing gold-
conjuga ted monoclona l an t ibod ies tha t b ind to
glucuronoxylomannan (GXM) cryptococcal antigen and is
capable of detecting all cryptococcal serotypes (A-D). One
drop (∼40 μL) of the patient sample is mixed with one drop
of diluent and a binary readout (two bands—test and con-
trol—for a positive test) is produced within 10 min if antigen
is detected. The assay has a number of qualities that make it
ideal for diagnostic testing in resource-limited settings, includ-
ing low cost, high sensitivity/specificity, point-of-care testing,
stability of diluent and test strips at room temperature with a
long shelf life (up to 2 years), minimal training requirement,
and no need for processing of samples (e.g., pretreatment, heat
inactivation) or specialized laboratory equipment. Further-
more, titers can be done using this assay for CRAG
quantification.
Using serum or plasma samples, the LFA has excellent
sensitivity and specificity and a high agreement with results
from other antigen-based tests [45, 65, 66•, 67, 68]. Serum
LFA had a sensitivity of 99.6 to 100 % in published studies
including patients with laboratory-confirmed cryptococcal
disease and a specificity of 92 % in a study of patients hospi-
talized with suspected meningitis (although this may be an
understatement as several of the Bfalse positives^ on LFA
may have actually been false negatives on reference tests)
[65, 69, 70•, 71]. Plasma LFA testing appears to perform
equivalently to serum testing [70•, 71]. Additionally, serum
LFA and LA had a 100 % agreement in a study from Tanzania
evaluating CRAG prevalence in asymptomatic, ART-naïve
patients, supporting LFA as a good alternative to other antigen
tests for use in CRAG screening for prevention [45]. Unpub-
lished data from Uganda and South Africa suggests that there
is 100 % agreement between whole blood, serum, and plasma
CRAG LFA testing, demonstrating that fingerstick is a viable
option for bedside detection of CRAG, particularly in settings
where phlebotomy is unavailable [72].
The LFA performs sub-optimally, however, with urine and
saliva samples. Although sensitive, LFA in urine lacks
specificity, leading to a poor positive predictive value
for cryptococcosis [46, 65, 69, 70•, 71]. Attempts to improve
the specificity of the urine assay by altering the diluent have
been unsuccessful, leading to a reduction in test sensitivity
compared to serum LFA as reference and continued sub-
optimal specificity (sensitivity decreasing from 100 % to
80 % and specificity increasing from 73.8 % to 91.5 %)
[46]. Using samples of saliva, a recent Ugandan study found
excellent specificity but poor sensitivity (88% in symptomatic
patients and only 27 % in asymptomatic patients) of the LFA
in detecting cryptococcal antigenemia using serum/plasma
samples for reference [73]. In a review of the published liter-
ature addressing performance of the LFA assay, median CSF
sensitivity was 100 %, and median specificity was 97.7 %. In
serum, median sensitivity was again 100 %, with median
specificity of 99.5 % [74].
Cost-Effectiveness of CRAG Screening
The cost per sample using the CRAG LFA is substantially
lower than other antigen test methodologies or culture. The
manufacturer offers the test for US$2 per sample in resource-
limited settings with a current delivered in-country real world
cost from local distributors of US$3–4. Further efficiencies in
distribution are possible. The cost in high-income countries is
$5 per LFA. Cost-effectiveness analyses of a CRAG Bscreen
and treat^ approach in antiretroviral therapy initiators with
CD4 counts <100 cells/μL have been performed in varied
settings, including Cambodia, South Africa, Uganda, and
Vietnam [17•, 18•, 39•, 52]. All studies have shown this
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approach to be extremely cost-effective, even using a low-
range prevalence estimate of 2 %. As these studies have
CRAG testing cost between US$4.13 per test and US$16.75
per test, as a screen and treat strategy, the LFA at US$2.50 per
test would further increase cost-effectiveness.
Costs of Cryptococcal Meningitis Management
In comparison to the costs of screening, the costs of manage-
ment of symptomatic cryptococcal meningitis are substantial-
ly greater. Costs of cryptococcal meningitis vary by country
but include costs of medications, healthcare personnel for 2-
week inpatient hospitalization, laboratorymonitoring for med-
ication toxicity, and finally costs of serial lumbar punctures
including manometers if available. In Uganda, total cost of
medical care for 2 weeks of induction therapy with
amphotericin and flucytosine is estimated at $467.48 [75•].
Given that flucytosine is unavailable, the total cost of care
with what is considered the next best regimen of amphotericin
+ fluconazole is $402.07, with the cost of medication making
up a small percentage of this total cost (23%). In South Africa,
the estimated cost for care of cryptococcal meningitis is $2883
[18•]. This variability is likely due to much higher cost of
personnel in South Africa. Estimated US costs for 14 days
of inpatient management of cryptococcal meningitis is $50,
000 with flucytosine alone costing approximately $9000 for a
70-kg adult [76].
Integrating Cryptococcal Antigen Screening
and Fluconazole Therapy into Routine
Care—Challenges and Opportunities
Integrating CRAG screening into routine HIV care
could potentially provide a platform for improved link-
age to care, promoting continuity in care while diminishing
attrition, and contributing to improved patient outcomes. As
an integrated practice, healthcare facilities could focus on the
more severely immunosuppressed patients, by having dedicat-
ed staff to follow up CD4 and CRAG test results, and ensure
that this population of patients (with CD4 <100 cells/μL)
returns to the clinic in a timely manner to receive the appro-
priate intervention, including fluconazole, if CRAG positive.
The timing of ART initiation among patients with asymptom-
atic cryptococcal antigenemia has not been studied; however,
current guidelines recommend initiatingARTafter the 2weeks
of high-dose fluconazole. Following the release of the 2011
WHO rapid advice guidelines on the diagnosis, prevention,
and management of cryptococcal disease in HIV-infected in-
dividuals, several countries have revised their national guide-
lines to reflect these changes; however, actual implementation
of these guidelines has been varied (Table 2) [57].
Several operational challenges must be addressed as screen
and treat programs are implemented. First, cryptococcal
screening must be integrated into routine management algo-
rithms for patients who require rapid ART initiation. Second,
for the program to succeed, patients found to have cryptococ-
cal antigenemia must be immediately traced, assessed, and
initiated on antifungal treatment before they develop menin-
gitis or die. Laboratory reporting and clinic tracing systems
need to be enhanced. Third, supply, procurement, and distri-
bution of CRAG tests and antifungal drugs to clinics must be
adequate and consistent, and nurses who identify patients with
antigenemia need to have the ability to initiate antifungal
treatment.
From the experience of an ongoing CRAG screening study
in Kampala Uganda, challenges of rolling out the CRAG
screening program include lack of adequate staff training
across all levels of health cadres, from laboratory, clinical,
and administrative staff, which limits the appreciation of pro-
gram ownership; lack of adequate logistics and the irregular
supply of CD4 testing reagents, which slows the screening
process; lack of CRAG screening tests at health facilities; lack
of a steady supply of fluconazole for preemptive treatment;
and, finally, poor referral systems in the absence of relevant
manpower to handle this very sick population. More often
than not, health facilities are ill equipped with the required
drugs and tests to manage patients with breakthrough
meningitis.
Conclusions
Significant improvement in cryptococcal diagnosis has oc-
curred along with a better understanding of cryptococcal man-
agement. By integrating CRAG screening and fluconazole
preemptive therapy as recommended by the WHO, the mor-
bidity and mortality occasioned by cryptococcal disease could
be drastically reduced. In the long term, with a subsiding
number of newly diagnosed HIV-infected individuals present-
ing to HIV care with lower CD4 counts, increasing numbers
of patients started on ART at CD4 counts >500 cells/μL, and
improved linkage to long-term HIV care, screen and treat
programs will become less expensive with fewer persons re-
quiring CRAG testing and fluconazole therapy. There still
remains the benefit of saving money to preemptively treat
patients who would otherwise develop cryptococcal meningi-
tis. Ideally, with perfect CRAG screening programs, one could
envision elimination of cryptococcal meningitis using
this screen and treat strategy, especially in sub-Saharan
Africa. However, challenges remain on how best to im-
plement such a strategy and a better understanding of
risk factors for breakthrough cryptococcal meningitis re-
mains to be elucidated.
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